TD Cowen raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $125 from $117 and keeps a Buy rating on the shares. The firm updated it model ahead of the data from the pivotal Ph. IIb trial of volixibat in PSC where they beleive volixibat will show a statistically significant reduction in pruritus vs. placebo which will support a filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion
- Mirum Pharmaceuticals completes enrollment in EXPAND study
- Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study
- Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI
- Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M